WEST HARRISON, NY / ACCESSWIRE / January 4, 2016 / The January Effect is a rally stemming from an increase in buying following December tax selling as investors create tax losses especially in small and micro-cap stocks. Measuring from Dec. 31st through Jan. 31st the Jan. percentage gains in shares of CEL-SCI Corporation (NYSE MKT: CVM) were 23% in 2015, 80% in 2014, 4% in 2013 and 17% in 2012. The average gain of 31% suggests shares could do very well in the first month of 2016.
This creates an entry point to profit not only from the January Effect but even more highly positive events which will follow later in 2016. More significant is the continuing progress and finally achieving full enrollment this summer of 880 newly diagnosed head and neck cancer patients in its global immunotherapy Phase III study. This is the largest head and neck cancer patient trial in history with 84 sites in 24 countries including in U.S., Canada, Israel and parts of Europe and Asia.
CEL-SCI's unique goal is to prove that injecting its Multikine drug regime for three weeks before surgery, radiation and/or chemotherapy will show at least a 10% improvement in overall patient survival. In contrast, other peer cancer immunotherapy companies, which require much longer treatment times, aim to boost the immune system after the tumor has recurred, when the immune system may have been debilitated by the toxicity from the earlier radiation and chemotherapy.
CEL-SCI is currently enrolling over one newly diagnosed cancer patient a day and picking up more momentum. Full enrollment of its trial is planned in 2016 with possible study completion in 2017. If the 10% improvement goal in patient survival is achieved with its Multikine treatment, CEL-SCI expects to submit a Biologics License Application to the FDA seeking approval of its Multikine drug regime. It could have the potential to become the fourth standard of care for head and neck cancer, preceding and joining surgery, chemotherapy and radiation.
Our complete in depth sponsored CEL-SCI Corporation profile can be found archived on our Flaherty Financial News website at http://www.flahertyfinancialnews.com/.
Direct Server Link to The Report - With the Modern Social Share Buttons: http://campaign.r20.constantcontact.com/render?ca=b0c84786-6dac-436f-931b-ac4862fee7e2&c=&ch
Direct Link to Flaherty Financial News Newsletter #53: http://archive.constantcontact.com/fs141/1101855435216/archive/1123343146975.html
About Flaherty Financial News Inc.
Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of interesting public companies. FFN was launched in 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers’ Association, Bob is a co-founder of their annual student scholarship program and their annual award for significant long-term achievement in financial journalism.